Navigation Links
Diabetes makes it hard for blood vessels to relax
Date:1/31/2008

osed with the recommendation the supplement not be used by heart attack patients. The supplement still is widely marketed.

The findings of increased arginase I activity in diabetes may limit other therapeutic approaches proposed for early endothelial dysfunction such as oral L-arginine supplementation, Drs. Thomas L. Luscher and Jan Steffel, of the University of Zurich Cardiovascular Research Institute write in an accompanying editorial. Although dietary L-arginine supplementation has been shown to exert vascular protective effects in certain clinical settings, this approach is unlikely to be effective in diabetes, if the results of this study can be confirmed by patients in vivo. In fact, the findings of Romera et al may provide a possible explanation for the unexpected neutral or even adverse effects of oral L-arginine in some clinical studies, in particular patients with coronary artery disease and infarction.

A short intravenous course of L-arginine may provide short-term improvement in blood vessel tone, Dr. Romero notes. However most of L-arginine ingested goes directly to the liver to be broken down, not the bloodstream where it can promote relaxation of blood vessels, Dr. Romero says.

Arginase also is associated with vascular problems related to aging, hypertension, sickle cell disease, atherosclerosis and erectile dysfunction, Dr. Romero says. L-citrulline already is taken by some sickle cell patients to reduce breath-taking fibrosis in their lungs. In addition to helping the body turn toxins into urea that can be safely eliminated from the body, arginase also helps in collagen formation and cell proliferation, but too much can be bad. In fact, Drs. Caldwell and Romero are pursuing studies of how increased arginase activity may harden blood vessel walls.


'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia
Source:Eurekalert

Page: 1 2

Related biology news :

1. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
2. Gender, coupled with diabetes, affects vascular disease development
3. Breakthrough research identifies how cells from pigs may cure diabetes
4. Botched production of insulin molecule may lead to diabetes
5. Joslin researchers uncover potential role of leptin in diabetes
6. Insulins brain impact links drugs and diabetes
7. Exercise improves thinking, reduces diabetes risk in overweight children
8. UVa Health System team uncovers genes role in type 1 diabetes
9. Childrens Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes
10. JDRF awards University of Copenhagen professor with grant to conduct innovative diabetes research
11. Cancer and arthritis therapy may be promising treatment for diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has ... Market 2015-2019" report to their offering. ... is a technology used for the identification of individuals. ... a person such as nose, jaw edges, mouth, and ...
(Date:12/11/2014)... blood pressure plays a role in human health has been ... for high blood pressure – was first described as a ... used in measuring blood pressure was invented in 1896. ... its triggers and its effects. In fact, recent findings have ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Attend the International Osteoporosis Foundation,s key regional meeting ... participate in an enriching scientific programme of direct ... faculty of leading experts from around the world. ... includes... Plenary sessions ...
... of more than 100 studies from around the world shows ... solvents is likely associated with a higher risk of developing ... print issue of Neurology , the medical journal of ... association, there was also a link between farming or country ...
... identified a new regulator for plant hormone signaling -- the ... help to improve production of fruits, vegetables and grains. ... 27 in the journal Proceedings of the National Academy ... controls cytokinin signaling by regulating the degradation of type-B response ...
Cached Biology News:KISS ME DEADLY proteins may help improve crop yields 2
(Date:1/22/2015)... Protocol Networks brings independent technology consulting ... brand-neutral, independent consultants, Protocol Networks has recently announced its ... the years, his company has attracted several clients in ... as well as others. With the success of these ...
(Date:1/22/2015)... WI (PRWEB) January 22, 2015 Dr. Greg ... the 12th annual Scripps Natural Supplements Pre-Conference seminar on probiotics ... Conference is an annual continuing education conference for health care ... and included the topic of probiotics in health. Dr. Leyer ...
(Date:1/22/2015)... Jersey , 22 de enero de 2015  El Dr. ... hoy su llamada a nominaciones para 2015. Este prestigioso ... hecho, o tiene el potencial para hacer, contribuciones destacadas ... se aceptarán hasta el 15 de marzo de 2015 ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... Feb. 9, 2011 HIGHLIGHTS:2010 Results (all percentages ... 2010 reported sales were $582 million, a new quarterly high. Q4 ... adjusted basis, respectively.  Full year 2010 sales increased 6% and 5% ... Q4 2010 reported diluted EPS was $0.76. Excluding restructuring costs ...
... YORK, Feb. 9, 2011 Reportlinker.com announces that ... its catalogue: Strategic Analysis of ... http://www.reportlinker.com/p0376721/Strategic-Analysis-of-European-Human-Machine-Interface-HMI-Market.html This research ... Europe primarily over the two broad categories of ...
... Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR ) ... release after the market closes on February 23, 2011. Due ... be hosting a conference call to discuss its fourth quarter ... Inspiration. Dedication. Innovation. ...
Cached Biology Technology:Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 3Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 4Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 5Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 6Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 7Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 8Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 9Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 10Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 11Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 12Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 13Reportlinker Adds Strategic Analysis of European Human Machine Interface (HMI) Market 2
... DNA120 is a dedicated concentrator for efficient ... of DNA/RNA. The integrated system combines the ... The compact design, automatic pump and rotor ... time; one for heater time), makes the ...
... (For small quantities of solvents with DNA ... concentrator/centrifugal evaporator systems respond to specific applications ... and safe concentration of heat-labile samples. The ... different of cold traps and a wide ...
... series of vacuum concentrators/centrifugal evaporators offers a ... to rapid and safe concentration of heat-labile ... with oil-free or high vacuum pumps, a ... selection of rotors (eliminating sample loss by ...
For relative and/or absolute quantification with standard accuracy requirements using MS or NMR instruments...
Biology Products: